Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

Emma Shtivelman, Robert Peter Gale, Eli Canaani · Nature · 1985 · 1.6K citations

Medicine, Molecular Biology, Molecular Genetics +11

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

Annelies de Klein, Ad Geurts van Kessel, Gerard C. Grosveld et al. · Nature · 1982 · 1.4K citations

Life Sciences, Genetics, Molecular Genetics +16

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +13